Sjögren’s syndrome: current therapies remain inadequate for a common disease

Bibliography

• FOX R: Classification criteria for Sjogren's syndrome. Rheumatic Disease Clinics of North America: Current Controversies in Rheumatology. (1994) 20:391–407.
   PubMed Web of Science ®Google Scholar
• FOX RI, MARUYAMA T: Pathogenesis and treatment of Sjogren's syndrome. Curr. Opin. Rheumatol. (1997) 9:393–399.
   PubMedGoogle Scholar
• THEOFILOPOULOS AN, KONO DH: The genes ofsystemic autoimmunity. Proc. Assoc. Am. Phys. (1999) 111:228–240.
   PubMedGoogle Scholar
• FOX RI: Epstein-Barr virus and human autoimmunediseases: possibilities and pitfalls. j Virol. Methods (1988) 241:1218–1221.
   Google Scholar
• SAITO I, SERVENIUS B, COMPTON T, FOX RI: Detectionof Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. J. Exp. Med. (1989) 169:2191–2198.
   PubMed Web of Science ®Google Scholar
• MIZOKAMI A, EGUCHI K, MORIUCHI R et al.: LOW copynumbers of human T-cell lymphotropic virus Type I (HTLV-I) tax-like DNA detected in the salivary gland of seronegative patients with Sjogren's syndrome in an HTLV-I endemic area. Scand. J. Rheumatol. (1998) 27:435–440.
   PubMed Web of Science ®Google Scholar
• GARCIA-CARRASCO M, RAMOS M, CERVERA R et al.:Hepatitis C virus infection in 'primary' Sjogren's syndrome: prevalence and clinical significance in a series of 90 patients. Ann. Rheum. Dis. (1997) 56:173–175.
   PubMed Web of Science ®Google Scholar
• JORGENSEN C, LEGOUFFE MC, PERNEY P et al.: Siccasyndrome associated with hepatitis C virus infection. Arthritis Rheum. (1996) 39:1166–1171.
   PubMed Web of Science ®Google Scholar
• TORNVVALL J, LANE TE, FOX RI, FOX HS: T cell attractantchemokine expression initiates lacrimal gland destruction in nonobese diabetic mice. Lab. Invest. (1999) 79:1719–1726.
   PubMed Web of Science ®Google Scholar
• FOX RI, TORNWALL J, MICHELSON P: Current issues inthe diagnosis and treatment of Sjogren's syndrome. Curr. Opin. Rheumatol (1999) 11:364–371.
   PubMedGoogle Scholar
• KONG L, OGAWA N, NAKABAYASHI T et al.: Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum. (1997) 40:87–97.
   PubMed Web of Science ®Google Scholar
• KONG L, OGAWA N, MCGUFF HS et al.: Bc1-2 family expression in salivary glands from patients with primary Sjogren's syndrome: involvement of Bax in salivary gland destruction. Clin. Immunol. Immunopa-thol. (1998) 88:133–141.
   PubMedGoogle Scholar
• FOX RI: Sjogren's syndrome. Pathogenesis and newapproaches to therapy. Adv. Exp. Med. Biol. (1998) 438:891–902.
   PubMedGoogle Scholar
• MANOUSSAKIS MN, DIMITRIOU ID, KAPSOGEORGOU EKet al.: Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome. Arthritis Rheum. (1999) 42:229–239.
   Google Scholar
• ALPERT S, KANG H, WEISSMAN I, FOX R: Granzyme Expression in SjOgren's Syndrome. Arthritis Rheum. (1994) 37:1048–1054.
   Web of Science ®Google Scholar
• ROBINSON CP, BRAYER J, YAMACHIKA S et al.: Transfer of human serum IgG to nonobese diabetic Igrnu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in SjOgren's syndrome. Proc. Natl. Acad. Sci. USA (1998) 95:7538–7543.
   PubMed Web of Science ®Google Scholar
• MIRCHEFF AK, LAMBERT RW, MAVES CA, GIEROW JP, WOOD RL: Subcellular organization of ion transporters in lacrimal acinar cells: secretagog-ue-induced dynamics. Adv. Exp. Med. Biol. (1994) 350:79–86.
   PubMedGoogle Scholar
• ASRANI AC, LUMSDEN AJ, KUMAR R, LAURIE GW: Gene cloning of BM180, a lacrimal gland enriched basement membrane protein with a role in stimulated secretion. Adv. Exp. Med. Biol. (1998) 438:49–54.
   PubMed Web of Science ®Google Scholar
• BOUDREAU N, SYMPSON CJ, WERB Z, BISSELL MJ: Suppression of ICEand apoptosis in mammary epithe-lial cells by ex tracellular matrix. Science (1995) 267:891–893.
   PubMed Web of Science ®Google Scholar
• SYMPSON CJ, TALHOUK RS, ALEXANDER CM et al.: Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branchingmorphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J. Cell Biol. (1994) 125:681–693.
   PubMed Web of Science ®Google Scholar
• WU AJ, LAFRENIE RM, PARK C et al.: Modulation of MMP-2 (gelatin ase A) and MMP-9 (gelatin ase B) by interferon-gamma in a human salivary gland cell line. J. Cell Physiol. (1997) 171:117–124.
   PubMed Web of Science ®Google Scholar
• FOX RI: SjOgren's syndrome. Controversies and progress. Clin. Lab. Med. (1997) 17:431–444.
   PubMedGoogle Scholar
• GILBARD JP: Dry eye: pharmacological approaches, effects and progress. Clao. J. (1996) 22:141–145.
   PubMedGoogle Scholar
• WILSON F: Adverse external ocular effects of topical ophthalmic medications. Surv. Ophthalmol. (1979) 2 4:57–86.
   Web of Science ®Google Scholar
• KATAYAMA I, KOYANO T, NISHIOKA K: Prevalence ofeyelid dermatitis in primary SjOgren's syndrome. Int. J. Dermatol. (1994) 33:421–424.
   PubMed Web of Science ®Google Scholar
• DRIVER PJ, LEMP MA: Meibomian gland dysfunction. Sun'. Ophthalmol. (1996) 40:343–367.
   PubMed Web of Science ®Google Scholar
• SEAL D, FICKER L, RAMAKRISHNAN M, WRIGHT P: Role of staphylococcal toxin production in blepharitis. Ophthalmology (1990) 97:1684–1688.
   PubMed Web of Science ®Google Scholar
• GUNAYDIN I, TERHORST T, ECKSTEIN A, DAIKELER T, KANZ L, KOTTER I: Assessment of keratoconjunctivitis sicca in patients with fibromyalgia: results of a prospective study. Rheumatol. Int. (1999) 19:7–9.
   PubMed Web of Science ®Google Scholar
• HUBER-SPITZY V, BAUMGARTNER I, BOHLER-SOMMEREGGER K, GRABNER G: Blepharitis - a diagnostic and therapeutic challenge. A report on 407 consecutive cases. Graefes Arch. Clin. Exp. Ophthalmol. (1991) 229:224–227.
   Google Scholar
• DOUGHERTY JM, MCCULLEY JP, SILVANY RE, MEYER DR:The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest. Ophthalmol. Vis. Sci. (1991) 32:2970–2975.
   PubMed Web of Science ®Google Scholar
• VELPANDIAN T, GUPTA SK, GUPTA YK, AGARWAL HC,BISWAS NR: Comparative studies on topical lomeflox a-cin and ciprofloxacin on ocular kinetic and experi-mental corneal ulcer. J. Ocul Pharmacol Ther. (1999) 15:505–511.
   PubMed Web of Science ®Google Scholar
• SALL K, STEVENSON OD, MUNDORF TK, REIS BL: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology (2000) 107:631–639.
   Google Scholar
• GAO J, SCHWALB TA, ADDEO JV, GHOSN CR, STERN ME: The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea (1998) 17:654–663.
   PubMed Web of Science ®Google Scholar
• GRATZEK AT, KASWAN RL, MARTIN CL, CHAMPAGNE ES,WHITE SL: Ophthalmic cyclosporine in equine keratitis and keratouveitis: 11 cases. Equine Vet] (1995) 27:327–333.
   PubMed Web of Science ®Google Scholar
• PERRY HD, DONNENFELD ED, ACHEAMPONG A et al.:Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetra-tion of topical 0 .5 % cyclosporine Ainto the cornea and anterior chamber. Clao. J. (1998) 24:159–165.
   Google Scholar
• SOTO-ROJAS AE, VILLA AR, SIFUENTES-OSORNIO J,ALARCON-SEGOVIA D, KRAUS A: Oral manifestations in patients with Sjö gr en's syndrome. J. Rheumatol. (1998) 25:906–910.
   PubMed Web of Science ®Google Scholar
• ASTOR FC, HANFT KL, CIOCON JO: Xerostomia: aprevalent condition in the elderly. Ear Nose Throat J. (1999) 7 8 :476–479.
   Google Scholar
• DANIELS TE, WHITCHER JP: Association of patterns oflabial salivary gland inflammation with keratocon-junctivitis sicca. Analysis of 618 patients with suspected SjOgren's syndrome. Arthritis Rheum. (1994) 37:869–877.
   PubMed Web of Science ®Google Scholar
• ATKINSON JC, FOX PC: SjOgren's syndrome: oral anddental considerations. J. Am. Dent. Assoc. (1993) 124:74–76.
   PubMed Web of Science ®Google Scholar
• ZAURA-ARITE E, TEN CATE JM: Effects of fluoride- andchlorhexidine-containing varnishes on plaque composition and on demineralization of dentinal grooves in situ [In Process Citation]. Eur. J. Oral Sci. (2000) 108:154–161.
   PubMed Web of Science ®Google Scholar
• FOX PC, VAN DER VEN PF, BAUM BJ, MANDEL ID: Pilocarpine for the treatment of x erostomia associated with salivary gland dysfunction. Oral Surg. Oral Med. Oral Pathol. (1986) 61:243–248.
   PubMedGoogle Scholar
• GREENSPAN D, DANIELS TE: Effectiveness ofpilocarpine in postradiation xerostomia. Cancer (1987) 59:1123–1125.
   PubMed Web of Science ®Google Scholar
• HORIOT JC, MAINGON P, BARILLOT I: Radiotherapy forhead and neck cancers including chemoradiotherapy. Curr. Opin. Oncol (1994) 6:272–276.
   PubMedGoogle Scholar
• VIVINO FB, AL-HASHIMI I, KHAN Z et al: PilocarpineTablets for the treatment of dry mouth and dry eye symptoms in patients with SjOgren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med. (1999) 1 5 9:174–181.
   Google Scholar
• FOX PC, MANDEL ID: Effects of pilocarpine on salivaryflow in patients with SjOgren's syndrome. Oral Surg. Oral Med. Oral Pathol. (1992) 74:315–318.
   PubMedGoogle Scholar
• NUSAIR S, RUBINOW A: The use of oral pilocarpine inxerostomia and SjOgren's syndrome. Semin. Arthritis Rheum. (1999) 28:360–367.
   PubMed Web of Science ®Google Scholar
• FOX R, PENTRONE J, CONDEMI R, FIFE P: Randomized,placebo controlled trial of SNI-2011, a novel M3 muscarinic receptor agonist, for the treatment of SjOgren's syndrome. Arthritis Rheum. (1998) 41 (suppl.):S288.
   Google Scholar
• IWABUCHI Y, MASUHARA T: Sialogic activities ofSNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen's syndrome. Gen. Pharmacol. (1994) 25:123–129.
   PubMedGoogle Scholar
• SLOMIANY BL, MURTY VL, PIOTROWSKI J, SLOMIANY A:Salivary mucins in oral mucosal defense. Gen. Pharmacol. (1996) 27:761–771.
   PubMedGoogle Scholar
• BRON AJ: The Doyne lecture. Reflections on the tears. Eye (1997) 11:583–602.
   Google Scholar
• BERRY M, ELLINGHAM RB, CORFIELD AP: Polydispersity of normal human conjunctival mucins. Invest. Ophthalmol. Vis. Sci. (1996) 37:2559–2571.
   PubMed Web of Science ®Google Scholar
• HICKS SJ, CARRINGTON SD, KASWAN RL, STERN ME, CORFIELD AP: Secreted and membrane bound ocular mucins from normal and dry eye dogs. Biochem. Soc. Trans. (1995) 23:537S.
   PubMed Web of Science ®Google Scholar
• IONTCHEVA I, OPPENHEIM FG, TROXLER RF: Human salivary mucin MG1 selectively forms heterotypic complexes with amylase, proline-rich proteins, statherin and histatins. J Dent. Res. (1997) 76:734–743.
   PubMed Web of Science ®Google Scholar
• SAARI H, HALINEN S, GANLOV K, SORSA T, KONTTINENYT: Salivary mucous glycoprotein MG1 in SjOgren's syndrome. Clin. Chim. Acta (1997) 2 5 9:83–96.
   Google Scholar
• ALBONE EF, HAGEN FK, SZPIRER C, TABAK LA: Molecular cloning and characterization of the gene encoding rat submandibular gland apomucin, Mucsmg. Glycoconj. J. (1996) 13:709–716.
   PubMed Web of Science ®Google Scholar
• ZARA J, HAGEN FK, TEN HAGEN KG, VAN WUYCKHUYSEBC, TABAK LA: Cloning and expression of mouse UDP-GaINAc: polypeptide N-acetylgalactos aminyltransferase-13. Biochem. Biophys. Res. Commun. (1996) 2 2 8:38–44.
   Google Scholar
• FERRACCIOLI GF, SALAFFI F, DE VITA S et al.: Interferonalpha-2 (IFN alpha 2) increases lacrimal and salivary function in SjOgren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin. Exp. Rheumatol. (1996) 14:367–371.
   Google Scholar
• SHIP JA, FOX PC, MICHALEK JE, CUMMINS MJ, RICHARDS AB: Treatment of primary SjOgren's syndrome with low-dose natural human interferon-alpha adminis-tered by the oral mucosal route: a Phase II clinical trial. IFN Protocol Study Group. J. Interferon Cytokine Res. (1999) 19:943–951.
   PubMed Web of Science ®Google Scholar
• SHIOZAWA S, TANAKA Y, SHIOZAWA K: Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with SjOgren's syndrome. J. Interferon Cytokine Res. (1998) 18:255–262.
   PubMed Web of Science ®Google Scholar
• LUNEL F, CACOUB P: Treatment of autoimmune and ex trahepatic manifestations of hepatitis C virus infection. J. Hepatol. (1999) 31:210–216.
   PubMed Web of Science ®Google Scholar
• UNOKI H, MORIYAMA A, TABARU A, MASUMOTO A, OTSUKI M: Development of SjOgren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol. (1996) 31:723–727.
   PubMed Web of Science ®Google Scholar
• FOX RI, DIXON R, GUARRASI V, KRUBEL S: Treatment of primary SjOgren's syndrome with hydroxychloro-quine: a retrospective, open-label study. Lupus (1996) 5 (Suppl. 1):S31–6.
   Google Scholar
• TISHLER M, YARON I, SHIRAZI I, YARON M: Hydroxy-chloroquine treatment for primary SjOgren's syndrome: its effect on salivary and serum inflamma-tory markers. Ann. Rheum. Dis. (1999) 58:253–256.
   PubMed Web of Science ®Google Scholar
• SKOPOULI FN, JAGIELLO P, TSIFETAKI N, MOUTSO-POULOS HM: Methotrexate in primary SjOgren's syndrome. Clin. Exp. Rheumatol (1996) 14:555–558.
   PubMed Web of Science ®Google Scholar
• PRICE EJ, RIGBY SP, CLANCY U, VENABLES PJ: A double blind placebo controlled trial of azathioprine in the treatment of primary SjOgren's syndrome. J. Rheumatol. (1998) 25:896–899.
   PubMed Web of Science ®Google Scholar
• DROSOS AA, SKOPOULI FN, COSTOPOULOS JS, PAPADIMITRIOU CS, MOUTSOPOULOS HM: Cyclosporin A (CyA) in primary SjOgren's syndrome: a double blind study. Ann. Rheum. Dis. (1986) 45:732–735.
   PubMed Web of Science ®Google Scholar
• OGASAWARA H, SEKIYA M, MURASHIMA A et al.: Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with SjOgren's syndrome. Clin. Rheumatol. (1998) 17:160–162.
   PubMed Web of Science ®Google Scholar
• SCHNABEL A, REUTER M, GROSS WL: Intravenous pulse cyclophosphamide in the treatment of interstitiallung disease due to collagen vascular diseases. Arthritis Rheum. (1998) 41:1215–1220.
   PubMed Web of Science ®Google Scholar
• NIEMELA RK, HAKALA M: Primary SjOgren's syndrome with severe central nervous system disease. Semin. Arthritis Rheum. (1999) 29:4–13.
   PubMed Web of Science ®Google Scholar
• KASSAN SS, THOMAS TL, MOUTSOPOULOS HM et al.: Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med. (1978) 89:888–892.
   PubMed Web of Science ®Google Scholar
• TALAL N: SjOgren syndrome and pseudolymphoma. Hosp. Pract. (Off Ed.) (1988) 23:71–75.
   PubMed Web of Science ®Google Scholar
• BENEDEK TG: Neoplastic associations of rheumatic diseases and rheumatic manifestations of cancer. Clin. Geriatr. Med. (1988) 4:333–355.
   PubMedGoogle Scholar
• FOX RI, ADAMSON III TC, FONG S et al: lymphocytephenotype and function of pseudolymphomas associ-ated with SjOgren's syndrome. J Clin. Invest. (1983) 72:52–62.
   PubMed Web of Science ®Google Scholar
• FOX R: SjOgr en's Syndrome: New approaches topathogenesis and therapy. Exp. Opin. Drug Ther. (1996) 5:1–27.
   Google Scholar
• STOSIC-GRUJICIC S, DIMITRIJEVIC M, BARTLETT RR: Anovel immunomodulating agent - leflunomide inhibits exwperimental autoimmune diabetes in mice. Transplant Proc. (1996) 28:3072–3073.
   PubMed Web of Science ®Google Scholar
• BARTLETT R, SCHLEYERBACH R: Immunopharma-cologic properties of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis in the rat. J Immunopharmacol. (1988) 7:7–18.
   Google Scholar
• SCHORLEMMER HU, KURRLE R, BARTLETT RR: Variousgraft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs). Inflamm. Res. (1997) 46 (Suppl. 2):S165–S166.
   Google Scholar
• STRAND V, FOX R, COHEN S et al.: Treatment of activerheumatoid arthritis with leflunomide compared with placebo and methotrexate. Izflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. (1999) 159:2542–2550.
   Google Scholar
• FOX RI, HERRMANN ML, FRANGOU CG et al.: Mechanismof action for leflunomide in rheumatoid arthritis. Clin. Immunol. (1999) 93:198–208.
   PubMed Web of Science ®Google Scholar
• XU X, BLINDER L, SHEN J et al: In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr /1pr mice. J Immunol. (1997) 159:167–174.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotr ex ate. N Engl. J. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• FOX R, EDWARDS C, TORNWALL Y, FOX H: sTNFbp prevents development of lymphoid infiltrates in the NOD mouse, a model for human SjOgren's Syndrome. Arthritis Rheum. (1999) 41 (Suppl.) :S181.
   Google Scholar
• COPE AP, LIBLAU RS, YANG XD et al.: Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. (1997) 185:1573–1584.
   PubMed Web of Science ®Google Scholar
• HANAUER SB: Review article: safety of infliximab in clinical trials. Aliment. Pharmacol. Ther. (1999) 13 (Suppl. 4):16–22.
   Google Scholar
• WATTS RA: Musculoskeletal and systemic reactions to biological therapeutic agents. CUIT. Opin. Rheumatol (2000) 12:49–52.
   PubMed Web of Science ®Google Scholar